Want to see AU:ZNO full AI Analyst Report?
ZNO Stock Chart & Stats
AU$0.08
<AU$0.01(8.00%)
At close: 4:00 PM EST
AU$0.08
<AU$0.01(8.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.18
Previous CloseN/A
Volume41.30K
Average Volume (3M)153.26K
Market Cap
AU$19.90M
Enterprise ValueAU$30.94
Total Cash (Recent Filing)AU$475.33K
Total Debt (Recent Filing)AU$625.70K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding406,211,760
10 Day Avg. Volume257,173
30 Day Avg. Volume153,260
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.62
Price to Sales (P/S)9.30
P/FCF Ratio-6.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Long‑lasting Antimicrobial Product DifferentiationZoono's core product claim—long‑lasting antimicrobial protection—supports premium positioning and repeat purchase potential across consumer and commercial channels. Structurally, durable efficacy claims can sustain B2B contracts and retail loyalty, aiding revenue stability over months as distribution scales.
Low Financial LeverageRelatively low debt reduces short‑term solvency pressure and interest burden, giving management flexibility to fund operations or restructure without heavy fixed obligations. Over a multi‑month horizon this lowers immediate bankruptcy risk despite operating losses, making turnaround financing easier to negotiate.
Modest FY2025 Revenue GrowthTop‑line growth in FY2025 indicates product uptake and some commercial traction despite prior volatility. If repeat purchasing and distribution expansion continue, higher volumes can leverage fixed costs and improve margins over several months, providing a credible path to scale if unit economics improve.
Bears Say
Persistent Negative Cash GenerationSustained operating cash outflows mean the business cannot internally fund working capital or growth, increasing reliance on external financing and raising dilution risk. Over the coming months, weak cash generation constrains marketing, inventory, and distribution investments needed to convert demand into durable profitability.
Deep Losses And Negative Gross ProfitNegative gross profit signals product pricing and/or cost issues: revenues do not cover direct costs. This structural margin deficiency undermines any revenue growth—without corrective pricing, cost reduction, or product mix changes, losses will persist and impede sustainable earnings recovery over months.
Eroded Equity Capital BaseMaterial equity erosion reduces the corporate cushion against losses and limits access to non‑dilutive capital. With a weakened balance sheet, the company is more vulnerable to shocks and has less leverage in financing talks, increasing the probability of dilutive raises or constrained strategic options in the medium term.
Zoono Group Limited News
ZNO FAQ
What was Zoono Group Limited’s price range in the past 12 months?
Zoono Group Limited lowest share price was AU$0.03 and its highest was AU$0.18 in the past 12 months.
What is Zoono Group Limited’s market cap?
Zoono Group Limited’s market cap is AU$19.90M.
When is Zoono Group Limited’s upcoming earnings report date?
Zoono Group Limited’s upcoming earnings report date is Aug 20, 2026 which is in 16 days.
How were Zoono Group Limited’s earnings last quarter?
Zoono Group Limited released its earnings results on Feb 23, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zoono Group Limited overvalued?
According to Wall Street analysts Zoono Group Limited’s price is currently Overvalued.
Does Zoono Group Limited pay dividends?
Zoono Group Limited pays a Notavailable dividend of AU$0.03 which represents an annual dividend yield of N/A. See more information on Zoono Group Limited dividends here
What is Zoono Group Limited’s EPS estimate?
Zoono Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zoono Group Limited have?
Zoono Group Limited has 406,211,760 shares outstanding.
What happened to Zoono Group Limited’s price movement after its last earnings report?
Zoono Group Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.896%.
Which hedge fund is a major shareholder of Zoono Group Limited?
Currently, no hedge funds are holding shares in AU:ZNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoono Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.69%
Trailing 12-Months
Company Description
Zoono Group Limited
Zoono Group Limited, along with its associated entities, specializes in the innovation, development, and global distribution of a variety of antimicrobial solutions, catering to both the New Zealand market and international clientele. Their product line features items such as hand cleansers, specialized textile applications, mold remediation treatments, and surface disinfectants. Zoono provides its services to a broad spectrum of industries, including the aviation, medical, early education, facilities management, transportation, academic, and hospitality sectors. The firm was established in 1986 and maintains its principal operations from Auckland, New Zealand.
Technical Analysis
Pental Ltd.
―
Mcpherson'S Limited
―
―
EVE Health Group Limited
―
Skin Elements Limited
―